参考文献/References:
[1] Ammirati E,Frigerio M,Adler ED,et al. Management of acute myocarditis and chronic inflammatory cardiomyopathy:an expert consensus document[J].?irc Heart Fail,2020,13(11):e007405.[2] Leone O,Veinot JP,Angelini A,et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology[J].?ardiovasc Pathol,2012,21(4):245-274.[3] Basso C. Myocarditis[J].? Engl J Med,2022,387(16):1488-1500.[4] Ammirati E,Veronese G,Bottiroli M,et al. Update on acute myocarditis[J].?rends Cardiovasc Med,2021,31(6):370-379.[5] Tsch?e C,Ammirati E,Bozkurt B,et al. Myocarditis and inflammatory cardiomyopathy:current evidence and future directions[J].?at Rev Cardiol,2021,18(3):169-193.?6] Schultheiss HP,Baumeier C,Aleshcheva G,et al.Viral myocarditis-from pathophysiology to treatment[J].? Clin Med,2021,10(22):5240.?7] Kawai C. From myocarditis to cardiomyopathy:mechanisms of inflammation and cell death:learning from the past for the future[J]. Circulation,1999,99(8):1091-1100. [8] Heymans S,Eriksson U,Lehtonen J,et al. The quest for new approaches in?yocarditis and inflammatory?ardiomyopathy[J]. J Am Coll Cardiol,2016,68(21):2348-2364.[9] Ozieranski K,Tyminska A,Jonik S,et al. Clinically suspected myocarditis in the course of severe acute respiratory syndrome novel coronavirus-2 infection:fact or fiction?[J].? Card Fail,2021,27(1):92-96.[10] Brociek E,Tymińska A,Giordani AS,et al. Myocarditis:etiology,pathogenesis,and their implications in clinical practice[J].?iology (Basel),2023,12(6):874.[11] Tan S,Day D,Nicholls SJ,et al. Immune checkpoint inhibitor therapy in?ncology:current uses and future directions:?ACC:CardioOncology?tate-of-the-Art Review[J].?ACC CardioOncol,2022,4(5):579-597.?12] Brahmer JR,Abu-Sbeih H,Ascierto PA,et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events[J].? Immunother Cancer,2021,9(6):e002435.[13] Axelrod ML,Meijers WC,Screever EM,et al. T cells specific for α-myosin drive immunotherapy-related myocarditis[J]. Nature,2022,611(7937):818-826.[14] Bruestle K,Hackner K,Kreye G,Heidecker B. Autoimmunity in acute myocarditis:how immunopathogenesis steers new directions for diagnosis and treatment[J].?urr Cardiol Rep,2020,22(5):28.?15] Merken J,Hazebroek M,van Paassen P,et al. Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy[J].?irc Heart Fail,2018,11(2):e004228.[16] Tsch?e C,van Linthout S,Spillmann F,et al. Targeting CD20+ B-lymphocytes in inflammatory dilated cardiomyopathy with rituximab improves clinical course:a case series[J].?ur Heart J Case Rep,2019,3(3):ytz131.[17] de Luca G,Campochiaro C,Sartorelli S,et al. Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis:a prospective cohort study[J].? Autoimmun,2020,106:102330.[18] Dandel M,Wallukat G,Englert A,et al. Long-term benefits of immunoadsorption in β(1)-adrenoceptor autoantibody-positive transplant candidates with dilated cardiomyopathy[J].?ur J Heart Fail,2012,14(12):1374-1388.?19] Düngen HD,Dordevic A,Felix SB,et al. β1-adrenoreceptor autoantibodies in heart failure:physiology and therapeutic implications[J].?irc Heart Fail,2020,13(1):e006155.[20] Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA),the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)[J].?ur Heart J,2022,43(41):4229-4361.?21] Cautela J,Zeriouh S,Gaubert M,et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis[J].? Immunother Cancer,2020,8(2):e001887.[22] Schultheiss HP,Piper C,Sowade O,et al. Betaferon in chronic viral cardiomyopathy (BICC) trial:effects of interferon-β treatment in patients with chronic viral cardiomyopathy[J].?lin Res Cardiol,2016,105(9):763-773.[23] Amdani SM,Kim HS,Orvedahl A,et al. Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support,intravenous immunoglobulin and pocapavir[J].?MJ Case Rep,2018,2018:bcr2017224133.[24] Kühl U,Lassner D,Wallaschek N,et al. Chromosomally integrated human herpesvirus 6 in heart failure:prevalence and treatment[J].?ur J Heart Fail,2015,17(1):9-19.?25] Manaresi E,Gallinella G. Advances in the development of antiviral strategies against parvovirus B19[J]. Viruses,2019,11(7):659.[26] Caforio AL,Pankuweit S,Arbustini E,et al. Current state of knowledge on aetiology,diagnosis,management,and therapy of myocarditis:a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases[J].?ur Heart J,2013,34(33):2636-2648d.[27] Tsch?e C,Elsanhoury A,Schlieker S,et al. Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence[J].?ur J Heart Fail,2019,21(11):1468-1469.[28] So-Armah K,Benjamin LA,Bloomfield GS,et al. HIV and cardiovascular disease[J].?ancet HIV,2020,7(4):e279-e293.?29] Robles AG,Pollice P,Guaricci AI,et al. A case of suspected eosinophilic myocarditis recognized by a fully noninvasive approach and safely treated with corticosteroids despite underlying hepatitis C virus-related hepatitis[J].?uture Cardiol,2020,16(5):413-418.[30] Sanders JM,Monogue ML,Jodlowski TZ,et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19):a review[J].?AMA,2020,323(18):1824-1836.?31] Heidenreich PA,Bozkurt B,Aguilar D,et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure:a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].? Am Coll Cardiol,2022,79(17):e263-e421.[32] Tsch?e C,van Linthout S,Klein O,et al. Mechanical unloading by fulminant myocarditis:LV-IMPELLA,ECMELLA,BI-PELLA,and PROPELLA concepts[J].? Cardiovasc Transl Res,2019,12(2):116-123.[33] Pinkert S,Dieringer B,Klopfleisch R,et al. Early treatment of Coxsackievirus B3-infected animals with soluble Coxsackievirus-adenovirus receptor inhibits development of chronic Coxsackievirus B3 cardiomyopathy[J].?irc Heart Fail,2019,12(11):e005250.[34] Kraft L,Erdenesukh T,Sauter M,et al. Blocking the IL-1β signalling pathway prevents chronic viral myocarditis and cardiac remodeling[J].?asic Res Cardiol,2019,114(2):11.?35] Abou-El-Enein M,Volk HD,Reinke P. Clinical development of cell therapies:setting the stage for academic success[J].?lin Pharmacol Ther,2017,101(1):35-38.?36] Miteva K,Pappritz K,Sosnowski M,et al. Mesenchymal stromal cells inhibit NLRP3 inflammasome activation in a model of Coxsackievirus B3-induced inflammatory cardiomyopathy[J].?ci Rep, 2018,8(1):2820.?37] Rieger AC,Myerburg RJ,Florea V,et al. Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy[J]. EBioMedicine,2019,48:377-385.[38] Tsch?e C,van Linthout S,J?er S,et al. Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis[J]. ESC heart failure,2020,7(5):2838-2852.[39] Kicman A,Toczek M. The effects of cannabidiol,a non-intoxicating compound of cannabis,on the cardiovascular system in health and disease[J].?nt J Mol Sci,2020,21(18):6740.?40] Branchereau M,Burcelin R,Heymes C. The gut microbiome and heart failure:a better gut for a better heart[J].?ev Endocr Metab Disord,2019,20(4):407-414.[41] Gil-Cruz C,Perez-Shibayama C,de Martin A,et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy[J].?cience,2019,366(6467):881-886.
相似文献/References:
[1]孙文静,孙林,赵新湘.心脏核磁共振在急性心肌炎中的研究进展[J].心血管病学进展,2015,(5):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
SUN Wenjing,SUN Lin,ZHAO Xinxiang.Evolution of Cardiac Magnetic Resonance Imaging in Acute Myocarditis[J].Advances in Cardiovascular Diseases,2015,(4):622.[doi:10.3969/j.issn.1004-3934.2015.05.026]
[2]陈文浩 张焕基 郭攸胜 张东辉.活检证实病毒性心肌炎的治疗策略及预后[J].心血管病学进展,2019,(5):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
Chen WenhaoZhang HuanjiGuo YoushengZhang Donghui.Treatment Strategy and Prognosis of Viral Myocarditis Confirmed by Biopsy[J].Advances in Cardiovascular Diseases,2019,(4):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
[3]陈丰 苏强 朱继金.高迁移率族蛋白B1在心脏炎症反应性疾病中的研究进展[J].心血管病学进展,2019,(8):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
CHEN Feng,SU Qiang,ZHU Jijin.Research Progress of HMGB1 in Myocardial Inflammatory Reactivity Disease[J].Advances in Cardiovascular Diseases,2019,(4):1111.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.010]
[4]张艺文 蔡琳 秦莉 杨晓倩 汪汉.基于网络药理学的参麦注射液治疗新型冠状病毒感染合并心肌炎的机制研究[J].心血管病学进展,2020,(10):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
ZHANG YiwenCAI LinQIN LiYANG XiaoqianWANG Han.Shenmai Injection for COVID-19 with Myocarditis Based on Network Pharmacology[J].Advances in Cardiovascular Diseases,2020,(4):1101.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.024]
[5]王斯 魏欣 肖乾凤 陈晓平.心肌炎的分类及治疗进展[J].心血管病学进展,2021,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
WANG Si,WEI Xin,XIAO Qianfeng,et al.The Classification and Treatment Progress of Myocarditis[J].Advances in Cardiovascular Diseases,2021,(4):337.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.012]
[6]杨晓倩 秦莉 张艺文 汪汉.苦参治疗新型冠状病毒感染合并心肌炎的网络药理学分析[J].心血管病学进展,2021,(6):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
YANG Xiaoqian,QIN Li,ZHANG Yiwen,et al.Network Pharmacological Analysis of Sophora Flavescens on Novel Coronavirus Infection complicated with Myocarditis[J].Advances in Cardiovascular Diseases,2021,(4):566.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[7]肖乾凤 王斯 刘燕扬 魏欣.免疫检查点抑制剂相关性心肌炎的诊治[J].心血管病学进展,2022,(7):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
Inhibitors-Related Myocarditis.Diagnosis and Treatment of Immune Checkpoint[J].Advances in Cardiovascular Diseases,2022,(4):610.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[8]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(4):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]